

# RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

NCT06823713

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Resolution Therapeutics Limited
<b>Enrollment</b>	30 participants

## Key Eligibility Criteria

---

### Inclusion (17)

- Individuals eligible to participate in this study must meet the following criteria:
  - Male or female age e18-75 years.
  - Patient confirms willingness/ability to comply with all study procedures.
  - Diagnosis of liver cirrhosis based on at least one of:
  - Clinical and radiological features that correlate with a diagnosis of cirrhosis.
- ... and 12 more (see full listing online)

### Exclusion (36)

- Liver cirrhosis due to:
  - any viral hepatitis, or
  - autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis.
  - Acute liver disease in the absence of underlying liver cirrhosis, including, but not limited to, drug induced liver injury.
  - Any current organ failure requiring more than outpatient supportive care, and not associated with the participant's qualifying hepatic decompensation event.
- ... and 31 more (see full listing online)

## Locations (14 total)

---

Hospital Universitari Vall d'Hebron, Barcelona, Spain  
Hospital Universitario Reina Sofía, Córdoba, Spain  
Hospital General Universitario Gregorio Marañón, Madrid, Spain  
... and 11 more locations